Summary & Overview
CPT 0480U: Metagenomic NGS for Pathogen Detection in Cerebrospinal Fluid
CPT code 0480U designates a proprietary metagenomic next-generation sequencing (NGS) test developed by Mayo Clinic to identify bacteria, viruses, fungi, and parasites in cerebrospinal fluid (CSF). As a PLA code, it applies to a single, manufacturer- or laboratory-specific assay that offers broad, hypothesis-free pathogen detection, which can be critical in diagnosing complex central nervous system infections when conventional testing is inconclusive.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for CSF metagenomic sequencing, typical sites of service, and how the test is described in billing terms. The publication outlines benchmark considerations for utilization and reimbursement, summarizes relevant policy and coverage developments affecting laboratory PLA codes, and highlights operational factors laboratories and providers should consider when submitting and documenting CPT code 0480U.
This summary is directed at a national audience and focuses on clinical utility, billing classification, and payer coverage landscape for CPT code 0480U. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 0480U is a Proprietary Laboratory Analyses (PLA) code for Bacteria, Viruses, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid (MSCSF) performed by Mayo Clinic. The test uses metagenomic next-generation sequencing (NGS) to detect and identify DNA and RNA from bacteria, viruses, fungi, and parasites in cerebrospinal fluid (CSF).
-
Service type: Metagenomic next-generation sequencing (NGS) respiratory pathogen and broad microbial detection assay applied to cerebrospinal fluid
-
Typical site of service: Clinical laboratory processing cerebrospinal fluid specimens; specimen collection typically occurs in inpatient or outpatient hospital settings or ambulatory clinics
Clinical & Coding Specifications
Clinical Context
A 52-year-old immunocompromised patient presents to the emergency department with fever, severe headache, photophobia, and altered mental status. Physical exam suggests meningeal irritation. A lumbar puncture is performed and cerebrospinal fluid (CSF) is sent for routine studies (cell count, glucose, protein), Gram stain and culture, and reflexively for advanced pathogen testing due to concern for atypical or undiagnosed central nervous system infection. The ordering clinician requests metagenomic next-generation sequencing (mNGS) of CSF to detect bacterial, viral, fungal, or parasitic nucleic acids when standard testing is non-diagnostic or when a broad, hypothesis-free pathogen search is clinically indicated.
The clinical workflow: after lumbar puncture, CSF is aliquoted and shipped under required conditions to the Mayo Clinic laboratory that performs the proprietary test reported with 0480U. The lab performs nucleic acid extraction, library preparation, and metagenomic sequencing of DNA and RNA, followed by bioinformatic analysis to identify pathogen sequences. Results are reported to the ordering clinician to guide targeted antimicrobial therapy, infection control decisions, or further diagnostic evaluation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use when no specific modifier applies to the service. |
| 22 | Increased procedural services | Use when work, time, or intensity substantially exceeds typical for the service due to complex specimen handling or extensive consultative reporting.
| 26 | Professional component | Use when only the professional (interpretation/reporting) component is billed separately from the technical/processing component.
| 52 | Reduced services | Use when the test is partially performed or limited versus the full intended procedure.
| 53 | Discontinued procedure | Use when specimen collection or processing is attempted but discontinued for patient safety or other valid reason.
| 62 | Two surgeons | Rare for lab tests, but use when two providers share significant professional responsibility for interpretation and both bill appropriately.
| 78 | Unplanned return to the operating/procedure room | Use when an unexpected return for repeat CSF collection or related procedure occurs during the postoperative global period.
| 80 | Assistant at surgery | Use if a qualified assistant contributes materially to specimen acquisition in an operative setting tied to the test.
| 82 | Assistant not available — CRNA or other | Use when assistant services are provided by a provider whose participation meets payer rules and is billed with this modifier.
| TC | Technical component | Use when billing only the laboratory’s technical component (sequencing, processing) separate from the professional interpretation.
| QX | Ordering physician(s) Personally Performed Service (Modifier for Modifier QK/QY) | Use when required by payer policy to indicate specific ordering/performance relationships for lab services.
| QY | Ordering physician certified and performed service | Use when the ordering provider meets specific certification/performance criteria relevant to payer rules.
| SH | Diagnostic service provided under a certified rural health clinic (RHC) | Use when service meets RHC billing rules.
| TG | Technical component performed in part by another entity | Use when the technical processing is subcontracted and documentation requires this indicator.
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Pathology | Laboratory directors and clinical pathologists who oversee testing and interpretation. |
| 207Q00000X | Infectious Disease | Infectious disease physicians who order and interpret mNGS results for patient management.
| 174400000X | Emergency Medicine | Emergency physicians who evaluate acutely ill patients and request CSF testing.
| 2086S0102X | Medical Microbiology | Clinical microbiologists involved in test validation and result oversight.
| 363L00000X | Neurology | Neurologists who evaluate central nervous system infections and incorporate results into care.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
A87.9 | Viral meningitis, unspecified | Viral meningitis is a common indication for CSF metagenomic testing when routine viral PCR panels are negative. |
| G00.9 | Bacterial meningitis, unspecified | When standard CSF culture and Gram stain are insufficient, mNGS can identify atypical bacterial pathogens.
| B99 | Other and unspecified infectious diseases | Use for infections of uncertain etiology where broad pathogen detection is required.
| G03.9 | Meningitis, unspecified | Non-specific meningitis diagnosis prompting broad-range CSF pathogen testing.
| A17.9 | Tuberculosis of nervous system, unspecified | CNS tuberculosis can be difficult to detect by conventional methods; mNGS may identify Mycobacterium sequences.
| B58.9 | Toxoplasmosis, unspecified | Parasitic CNS infections such as Toxoplasma can be detected by nucleic acid-based metagenomic methods.
| B44.9 | Aspergillosis, unspecified | Fungal CNS infections may be detected by CSF mNGS when culture and antigen testing are negative.
| R41.82 | Altered mental status, unspecified | Symptom code associated with presentations that trigger CSF evaluation and advanced pathogen testing.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
62270 | Spinal puncture, therapeutic or diagnostic (lumbar puncture) | Performed before 0480U to obtain CSF specimen for metagenomic sequencing. |
| 87798 | Infectious agent detection by nucleic acid (e.g., PCR), multiple organisms, multiplex; unlisted multiplex nucleic acid-based tests | May be used for other molecular CSF pathogen panels; often ordered in parallel or prior to mNGS.
| 88305 | Level IV surgical pathology, gross and microscopic examination | Used if tissue or cytology from CNS is submitted in conjunction with CSF testing for comprehensive diagnostic evaluation.
| 80502 | Infectious agent antibody detection, single step method (e.g., rapid), each agent | Serologic tests that may accompany CSF mNGS to evaluate systemic immune response to suspected pathogens.
| 0001U | Metagenomic sequencing or other proprietary PLA codes (example of PLA usage) | Illustrates the class of Proprietary Laboratory Analyses (PLA) codes to which 0480U belongs; other PLA codes may be billed for different vendor-specific tests performed in the diagnostic pathway.